-
Menopausal hormone therapy and risk of VTE and AD; patients' understanding of chemotherapy benefits; and FDA actions.
-
-
-
Piriformis syndrome remains an elusive diagnosis and neurologists should avoid recommendations for surgery interventions.
-
Epilepsy is associated with behavioral, psychiatric, cognitive, and social comorbidities. The associated comorbidities change across the lifespan of a person with epilepsy. Early detection and treatment of these comorbidities has the potential to significantly improve quality of life for patients with epilepsy.
-
The authors provide evidence that vascular endothelial growth factor (VEGF)-receptor inhibitors by themselves can trigger a painful neuropathy and can aggravate paclitaxel-induced neuropathy in mice by interfering with the neuroprotective effects of VEGF.
-
Stroke Incidence May Be Increasing in Younger People; Cancer May Be a Risk Factor for Ischemic Stroke; Physical Exercise Reduces White Matter Lesion Burden and Brain Atrophy in the Elderly; Serious Cardiac Arrhythmias May Occur During First 72 Hours After Stroke
-
Fatal headaches are associated with age over 50, loss of consciousness and collapse, and worst/thunderclap character of the headache.
-
Nightly melatonin improved objective and subjective sleep quality in a small number of patients who were taking beta-blockers for hypertension.
-
The FDA has approved an ethyl ester of eicosapentaenoic acid (EPA) to treat hypertriglyceridemia. It is the second drug in this class after Lovaza, which contains esters of both EPA and DHA (docosahexaenoic acid). Icosapent ethyl is marketed by Amarin Pharmaceuticals, a Dublin, Ireland-based company, as Vascepa.
